The detailed sequence of events following ECM binding to the integrin is not known, but the β-subunit cytoplasmic domain interacts directly with talin, and talin interacts with both vinculin and ...

The deal is expected to close sometime in the third quarter. MORF-057 is an α4β7 integrin inhibitor currently in a pair of phase 2 trials in ulcerative colitis and a third in Crohn’s disease.